openPR Logo
Press release

Animal Replacement Technologies - Convertible Bond Offering

07-23-2007 04:47 PM CET | Health & Medicine

Press release from: Animal Replacement Technologies

/ PR Agency: Animal Replacement Technologies
This synthetic human thigh (above) has been used to train surgeons to perform total hip replacements, to test femoral puncture closure devices, and in ballistics testing.

This synthetic human thigh (above) has been used to train surgeons to perform total hip replacements, to test femoral puncture closure devices, and in ballistics testing.

Animal Replacement Technologies announced today the availability of $1 million USD in convertible bonds in conjunction with their IPO (Initial Private Offering). These securities will pay 15% annually in quarterly installments and may be exchanged for common stock either upon demand or at the company's first organized equity offering (scheduled for late 2008). This opportunity is open to individuals, business entities, and educational institutions, and will involve up to $1 USD in convertible debt. A complete prospectus is available for review by potential investors.

Animal Replacement Technologies is a high-tech startup company based in Sarasota, Florida (USA) that develops the world's most sophisticated synthetic human cadavers, body parts, and tissues. These patented and award-winning products employ replaceable muscles, tendons, veins, arteries, and organs, all made from novel materials that mimic the structural, chemical, and mechanical properties of living human tissue. Such products are used by Fortune 500 medical device manufacturers to replace live animals in product development tests, by hospitals in surgical training, and by university medical schools in cutting-edge medical education programs.

Developers, researchers, and educators use Animal Replacement Technologies' products to perform highly compelling benchmarking studies. Such tests allow the developer to illustrate performance differences between prototype variants or prototypes and previously released devices. Used in this capacity, these products are the best tool available for supporting substantial equivalence claims to the FDA.

"There is no rubber, glass, or plastic in our products", says Dr. Christopher Sakezles, the President of Animal Replacement Technologies. "Each one of our extensive library of synthetic human tissues is designed on the basis of tests performed on live tissue, and much like the real thing our tissue analogs are composed of water, fibers, and salts. In fact, each component we make, such as an aortic arch, is itself comprised of multiple complex constructions . . . these are by far the world's most sophisticated and advanced synthetic body parts."

Dr. Christopher Sakezles
President, Chief Technology Officer
Animal Replacement Technologies
2522 Trailmate Drive
Sarasota, Florida 34243
Main: 941-727-0488
Fax: 941-727-0489
www.anireptec.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Animal Replacement Technologies - Convertible Bond Offering here

News-ID: 24558 • Views: 3133

More Releases from Animal Replacement Technologies

Synthetic Human Tissues E-Commerce Site
Animal Replacement Technologies announced today the launch of their E-commerce site (store.anireptec.com) for North America and Europe. A full range of synthetic human tissues and body parts are now available for purchase on the site via, credit card, check, or purchase order. Animal Replacement Technologies, based in Florida, USA, develops sophisticated synthetic human tissues and body parts for the medical device, consumer product, and military technology industries. This technology employs replacable
Animal Replacement Technologies - Stock Offering
Animal Replacement Technologies announced today the opening of a new (Series A) private stock offering to fund initial expansion. This opportunity is open to individuals, business entities, and educational institutions, and will involve the placement of up to 1 million shares of common stock at $1 USD per share. A complete prospectus is available for review by potential investors. Animal Replacement Technologies is a high-tech startup company based in Sarasota, Florida
Second Generation Vascular Lesion Models
Animal Replacement Technologies announced today the launch of their second-generation arterial lesions. These lesions are more sophisticated that the original chronic total occlusion models, and are designed to integrate with the company\'s current peripheral, coronary, and cerebral vascular products. these may be mounted in straight or branched sections as small as 1mm in diameter, may be softcap or hardcap, chronic total occlusions or characterized by a particular TIMI flow, and
Animal Replacement Technologies - Chief Operating Officer Search
Animal Replacement Technologies announced today the opening of a search for the position of Chief Operating Officer. This new position shall report directly to the President, and will carry executive responsibility for fundraising, sales and marketing, and general business administration. The individual ideally suited for this position will have an MBA from a reputable university and executive-level experience in the medical device, pharmaceutical, or biotechnology industries. Animal Replacement Technologies, based in

All 5 Releases


More Releases for USD

$100,000,000 USD job contract for travel - $3,000,000 USD referral commission.
Khoja Consultants invites applications for companies, teams or venture capitalists for a $100,000,000 USD job contract for travel. The selected company will be providing all accommodations and expenses for a 6-month long business trip around the world. Khoja Consultants expects five-star treatment including close security with private planes, hotels, secured vehicles and helicopters if necessary. More details on the job contract and application are provided at - www.KhojaConsultants.com. There
Agriculture Robots worth USD 3.5 billion market
According to Goldstein Research, the rising demand for agriculture robots is being driven by a numerous factors including global population growth, increasing strain on the food supply and decreasing availability of farm workers in developed countries. Global agriculture robots market segmentation includes products types such as driverless tractors, milking robots, potato sorting system, unmanned aerial vehicles and other. The market for agricultural robots is emerging at a rapid pace, with
Polyurethane Dispersions Market worth USD 2.04 Billion USD by 2020
The report " Polyurethane Dispersions Market by Type (Water-Based Polyurethane Dispersions and Solvent-Based Polyurethane Dispersions), by Application (Coatings, Adhesives & Sealants, Synthetic Leather Production, Fiber Glass Sizing, and Others) - Trends & Forecasts to 2020", The global polyurethane dispersions market is projected to reach USD 2.04 Billion by 2020 at a CAGR of 6.8% between 2015 and 2020. This growth is fueled by the high potential from the textile and
Retail Analytics Market worth USD 5.1 Billion USD by 2020
According to a new market research report "Retail Analytics Market by Business Function (Marketing and Customer Analytics, Merchandizing and In-Store Analytics, Supply Chain Analytics, Strategy and Planning), by Type, by Solutions and by Services - Global Forecast and Analysis to 2020", defines and segments the global retail analytics market on the basis of business function, solutions, services, deployment types, and regions along with providing an in-depth analysis and market size
Albumin Market USD 300 Million by 2020
According to a market research report Albumin Market 2013-2020, published by iHealthcareAnalyst, Inc., the global albumin market is estimated to reach USD 300 Million in 2020, expanding at a CAGR of 2.4% from 2016 to 2020. Visit the Albumin Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/albumin-market/ The global albumin market segmentation is based on type (human serum albumin, bovine serum albumin, recombinant albumin), and its applications (drug formulation and drug delivery, vaccines, components
Nanomedicine Market USD 170 Billion by 2020
The global nanomedicine market is estimated to reach USD 170 Billion in 2020, growing at a CAGR of 8.9% from 2016 to 2020, according to a market research report Nanomedicine Market 2013-2020, published by iHealthcareAnalyst, Inc. Visit the Nanomedicine Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/nanomedicine-market/ Nanomedicine is the medical application of nanotechnology that ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of